Insider Selling: Bolt Biotherapeutics (NASDAQ:BOLT) COO Sells $16,297.88 in Stock

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) COO Grant Yonehiro sold 4,909 shares of Bolt Biotherapeutics stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $3.32, for a total transaction of $16,297.88. Following the transaction, the chief operating officer owned 24,119 shares of the company’s stock, valued at $80,075.08. The trade was a 16.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Grant Yonehiro also recently made the following trade(s):

• On Friday, September 18th, Grant Yonehiro sold 6,850 shares of Bolt Biotherapeutics stock. The stock was sold at an average price of $3.24, for a total value of $22,194.00.
• On Wednesday, September 16th, Grant Yonehiro sold 1,417 shares of Bolt Biotherapeutics stock. The shares were sold at an average price of $3.77, for a total value of $5,342.09.

Bolt Biotherapeutics Stock Up 0.8%

BOLT stock traded up $0.03 on Monday, reaching $3.59. 22,454 shares of the company traded hands, compared to its average volume of 27,365. The firm has a fifty day simple moving average of $3.84 and a 200-day simple moving average of $4.29. The company has a market cap of $6.93 million, a P/E ratio of -0.22 and a beta of 1.09. Bolt Biotherapeutics, Inc. has a one year low of $3.10 and a one year high of $7.20. The company has a debt-to-equity ratio of 1.47, a current ratio of 2.61 and a quick ratio of 2.61.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its earnings results on Tuesday, August 11th. The company reported ($4.57) EPS for the quarter, missing analysts’ consensus estimates of ($3.39) by ($1.18). Bolt Biotherapeutics had a negative return on equity of 126.23% and a negative net margin of 611.47%.The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.50 million. Research analysts anticipate that Bolt Biotherapeutics, Inc. will post -11.1 earnings per share for the current year.

Analyst Ratings Changes

BOLT has been the topic of several recent analyst reports. Rodman & Renshaw initiated coverage on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. They set a “buy” rating and a $22.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Friday, July 17th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $14.50.

Institutional Investors Weigh In On Bolt Biotherapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its stake in shares of Bolt Biotherapeutics by 40.3% in the 1st quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock worth $312,000 after buying an additional 22,200 shares during the last quarter. T3 Companies LLC bought a new stake in shares of Bolt Biotherapeutics in the fourth quarter worth $208,000. Finally, Nan Fung Group Holdings Ltd purchased a new stake in Bolt Biotherapeutics during the second quarter valued at $19,250. 86.70% of the stock is currently owned by hedge funds and other institutional investors.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s platform is designed to stimulate the body’s innate and adaptive immune systems to recognize and attack tumor cells.

Bolt’s technology includes Boltbody™ immune-stimulating antibody conjugates, or ISACs. These therapies are intended to combine the targeting capabilities of antibodies with immune-activating components that can recruit and enhance the activity of immune cells within the tumor microenvironment.

The company’s development programs have included BDC-1001, an investigational HER2-targeted ISAC for the treatment of HER2-expressing solid tumors, and BDC-3042, an investigational antibody intended to activate macrophages through the Dectin-2 pathway.